| Dr Amy Elizabeth Flischel, MD | |
|
1010 Lakeland Pl, Flowood, MS 39232-6678 | |
| (601) 815-2005 | |
| Not Available |
| Full Name | Dr Amy Elizabeth Flischel |
|---|---|
| Gender | Female |
| Speciality | Dermatology |
| Experience | 17 Years |
| Location | 1010 Lakeland Pl, Flowood, Mississippi |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1972781037 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | 27767 (Mississippi) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of Mississippi Med Center | Jackson, MS | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| State Of Mississippi - University Of Mississippi Medical Center | 1850293036 | 804 |
News Archive
Neurocrine Biosciences, Inc. announced today that NBI-98854, a highly selective small molecule VMAT2 inhibitor, showed a statistically significant reduction in tardive dyskinesia during the six weeks of placebo-controlled treatment in the Kinect 3 clinical trial. This Phase III trial included moderate to severe tardive dyskinesia patients with underlying schizophrenia, schizoaffective disorder, bipolar or major depressive disorder.
Trastuzumab emtansine significantly delays disease progression compared with standard therapy in women with human epidermal growth factor receptor-2-positive metastatic breast cancer, show study data presented at the American Society of Clinical Oncology Annual Meeting in Chicago, Illinois, USA.
"Ahead of the International AIDS Conference next week in Washington, D.C., Martin Bloem, chief of Nutrition and HIV Policy at the World Food Programme, shares the impact of food and nutrition on the HIV response," in this post in the ONE Blog.
A team of cancer researchers at Cold Spring Harbor Laboratory (CSHL) has solved the mystery of how one of the most powerful of the body's natural tumor-suppressing proteins, called Chd5, exerts its beneficial effects.
Researchers at the Pontif-cia Universidade Cat-lica do Paran- and Instituto Carlos Chagas have evaluated the therapeutic potential of purified and expanded CD133+ cells human umbilical cord blood (HUCB)-derived in treating myocardial infarction by intramyocardially injecting them into a rat model. Patients who have high cardiovascular risks have fewer endothelial progenitor cells (EPCs) and their EPCs exhibit greater in vitro senescence.
› Verified 2 days ago
| Entity Name | State Of Mississippi - University Of Mississippi Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154317527 PECOS PAC ID: 1850293036 Enrollment ID: O20090414000575 |
News Archive
Neurocrine Biosciences, Inc. announced today that NBI-98854, a highly selective small molecule VMAT2 inhibitor, showed a statistically significant reduction in tardive dyskinesia during the six weeks of placebo-controlled treatment in the Kinect 3 clinical trial. This Phase III trial included moderate to severe tardive dyskinesia patients with underlying schizophrenia, schizoaffective disorder, bipolar or major depressive disorder.
Trastuzumab emtansine significantly delays disease progression compared with standard therapy in women with human epidermal growth factor receptor-2-positive metastatic breast cancer, show study data presented at the American Society of Clinical Oncology Annual Meeting in Chicago, Illinois, USA.
"Ahead of the International AIDS Conference next week in Washington, D.C., Martin Bloem, chief of Nutrition and HIV Policy at the World Food Programme, shares the impact of food and nutrition on the HIV response," in this post in the ONE Blog.
A team of cancer researchers at Cold Spring Harbor Laboratory (CSHL) has solved the mystery of how one of the most powerful of the body's natural tumor-suppressing proteins, called Chd5, exerts its beneficial effects.
Researchers at the Pontif-cia Universidade Cat-lica do Paran- and Instituto Carlos Chagas have evaluated the therapeutic potential of purified and expanded CD133+ cells human umbilical cord blood (HUCB)-derived in treating myocardial infarction by intramyocardially injecting them into a rat model. Patients who have high cardiovascular risks have fewer endothelial progenitor cells (EPCs) and their EPCs exhibit greater in vitro senescence.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Amy Elizabeth Flischel, MD 504 Clinton Center Drive, Cbo Suite 4300, Clinton, MS 39056-8709 Ph: (016) 815-2005 | Dr Amy Elizabeth Flischel, MD 1010 Lakeland Pl, Flowood, MS 39232-6678 Ph: (601) 815-2005 |
News Archive
Neurocrine Biosciences, Inc. announced today that NBI-98854, a highly selective small molecule VMAT2 inhibitor, showed a statistically significant reduction in tardive dyskinesia during the six weeks of placebo-controlled treatment in the Kinect 3 clinical trial. This Phase III trial included moderate to severe tardive dyskinesia patients with underlying schizophrenia, schizoaffective disorder, bipolar or major depressive disorder.
Trastuzumab emtansine significantly delays disease progression compared with standard therapy in women with human epidermal growth factor receptor-2-positive metastatic breast cancer, show study data presented at the American Society of Clinical Oncology Annual Meeting in Chicago, Illinois, USA.
"Ahead of the International AIDS Conference next week in Washington, D.C., Martin Bloem, chief of Nutrition and HIV Policy at the World Food Programme, shares the impact of food and nutrition on the HIV response," in this post in the ONE Blog.
A team of cancer researchers at Cold Spring Harbor Laboratory (CSHL) has solved the mystery of how one of the most powerful of the body's natural tumor-suppressing proteins, called Chd5, exerts its beneficial effects.
Researchers at the Pontif-cia Universidade Cat-lica do Paran- and Instituto Carlos Chagas have evaluated the therapeutic potential of purified and expanded CD133+ cells human umbilical cord blood (HUCB)-derived in treating myocardial infarction by intramyocardially injecting them into a rat model. Patients who have high cardiovascular risks have fewer endothelial progenitor cells (EPCs) and their EPCs exhibit greater in vitro senescence.
› Verified 2 days ago
Dr. Miriam J. Shatley, M.D. Dermatology Medicare: May Accept Medicare Assignments Practice Location: 108 Belle Meade Pointe, Flowood, MS 39232 Phone: 601-992-7002 | |
Dr. Anna Cole Asher, M.D. Dermatology Medicare: May Accept Medicare Assignments Practice Location: 108 Belle Meade Pt, Flowood, MS 39232 Phone: 601-992-7002 Fax: 601-992-0406 |